Paper Details

  1. Home
  2. Paper Details

The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial.

Author: BensonEric A, CallaghanJohn T, DestaZeruesenay, DexterPaul R, EadonMichael T, FultonCathy R, GuffordBrandon T, GuptaSamir K, HaasDavid M, HolmesAnn M, KreutzRolf P, LevyKenneth D, PiersonRebecca C, PrattVictoria M, RosenmanMarc B, ShuggTyler, SkaarTodd C, TillmanEmma M, VuppalanchiRaj, ZangYong, ZhangPengyue

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Pragmatic Clinical TrialA trial conducted in a real-world clinical setting. It evaluates the effectiveness of interventions in everyday healthcare environments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigates the impact of pharmacogenetic testing on adverse drug events (ADEs) in patients receiving new prescriptions for certain medications. The study found no overall reduction in ADEs after pharmacogenetic testing but did identify a potential benefit in specific drug categories, suggesting that further research is needed to optimize the use of pharmacogenetic testing.
Paper Details　
Original Abstract of the Article :
Adverse drug events (ADEs) account for a significant mortality, morbidity, and cost burden. Pharmacogenetic testing has the potential to reduce ADEs and inefficacy. The objective of this INGENIOUS trial (NCT02297126) analysis was to determine whether conducting and reporting pharmacogenetic panel te...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/s41397-023-00315-w

データ提供：米国国立医学図書館（NLM）

Pharmacogenetic Testing: A Personalized Approach to Drug Therapy

Adverse drug events (ADEs) pose a significant challenge in healthcare, impacting patient safety and increasing healthcare costs. This study explores the potential of pharmacogenetic testing to reduce ADEs by tailoring drug therapy to individual genetic profiles. The researchers conducted a pragmatic clinical trial to determine the impact of pharmacogenetic testing on ADE frequency. While the overall results showed no significant difference in ADEs, subgroup analyses revealed a reduction in serious ADEs and death in individuals receiving pharmacogenetic testing for specific medications. This study provides valuable insights into the potential benefits and limitations of pharmacogenetic testing in personalized medicine.

Tailoring Treatment: The Promise of Pharmacogenetic Testing

The study suggests that pharmacogenetic testing may offer a promising strategy for reducing ADEs, particularly for specific medications. The researchers observed a reduction in serious ADEs and death in individuals receiving pharmacogenetic testing for aripiprazole and serotonin or serotonin-norepinephrine reuptake inhibitors. These findings highlight the potential of personalized medicine to improve patient outcomes and minimize the risks of drug therapy.

Navigating the Future of Personalized Medicine: Pharmacogenetic Testing

This research opens up a new frontier in personalized medicine, exploring the potential of pharmacogenetic testing to tailor drug therapy to individual genetic profiles. The study's findings, while encouraging, emphasize the need for further research to refine the application of pharmacogenetic testing and maximize its impact on patient safety and well-being. As we continue to advance in personalized medicine, pharmacogenetic testing may play an increasingly pivotal role in optimizing drug therapy and enhancing patient outcomes.

Dr. Camel's Conclusion

Pharmacogenetic testing, like a compass navigating a vast desert, holds the potential to guide us towards a more personalized approach to drug therapy. The study's findings, while not conclusive, offer a glimmer of hope for reducing ADEs and improving patient safety. As we delve deeper into the realm of personalized medicine, pharmacogenetic testing may emerge as a transformative force, allowing us to tailor treatment strategies to the unique genetic makeup of each individual.

Date :
  1. Date Completed 2023-11-29
  2. Date Revised 2023-11-29
Further Info :

Pubmed ID

37689822

DOI: Digital Object Identifier

10.1038/s41397-023-00315-w

Related Literature

Article Analysis
・Side Effects of aripiprazole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.